Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11039676 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL226936 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL3708731 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL3708709 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL6048331 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL535863 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL8732941 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL11423768 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP2C19USP2 | |
| SCHEMBL18249750 | 0.96 | ALDH1A1 (0.40) | ALDH1A1TSHRCYP2C19 | |
| SCHEMBL4612532 | 0.95 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | claimed |
| CN-112074544-A | Polymerizable monomer and polymerization method thereof | 阿莱恩技术有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| WO-2013046041-A1 | PYRIDINYLPYRAZOLES FOR USE AS KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-04-04 | — | — | WO | disclosed |
| US-7297804-B2 | Catalytic composition of organotin compounds | CHEMTURA ORGANOMETALICS GMBH (DE) | 2007-11-20 | — | — | US | disclosed |
| US-20060047101-A1 | Catalytic composition of organotin compounds | CHEMTURA ORGANOMETALLICS GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
| US-20030146019-A1 | Board and ink used for forming conductive pattern, and method using thereof | FUJIFILM CORPORATION (JP) | 2003-08-07 | — | — | US | disclosed |
| US-4837225-A | ENCEPHALOTROPIC AND PSYCHOTROPIC EFFECTS | CASSELL AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | DCK, MAP3K2, MAP3K19 | ALDH1A1 4455/4885TSHR 1694/4885CYP2C19 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.